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Background: Propofol lipid emulsion supports bacterial growth and various outbreaks of postoperative infection are attributed 
to extrinsic contamination. This study’s objectives were to ascertain propofol administration practices among South African 
anaesthesiologists and to determine the influence of the 2014 South African Society of Anaesthesiologists (SASA) Guidelines for 
Infection Control in Anaesthesia.
Methods: A total of 1 598 SASA members were invited to participate anonymously and 634 replies were received. Using a risk-
scoring system developed from 13 questionnaire items, 542 respondents who administer propofol infusions were stratified into 
Low-, Moderate-, High- and Very High-Risk groups.
Results: The majority (65%) of the 542 participants who administer propofol infusions were classified as Moderate Risk, 29% as 
Low Risk and 6% as High and Very High Risk. Some 61% were aware of the SASA Guidelines, of whom 47.3% had studied them. 
The median risk-score of the Studied Guidelines group was significantly smaller (p < 0.001). They included a greater proportion 
who were categorised as low risk (58% vs. 45%) and a lower proportion who were moderate risk (38% vs. 51%). Proportions of 
high-risk individuals did not differ. Of the total 634 respondents, 247 used rubber-stoppered vials of whom 28% had studied the 
SASA Guidelines; 20% of the Studied Guidelines group often/always shared vial contents between patients versus 12% of those 
who had not studied them (p = 0.13). Conversely, 40% (studied group) versus 13.6% (not-studied group) often/always wiped the 
diaphragm and seldom/never shared vial contents between patients (p < 0.0001). In all, 25% of the total 634 respondents often/
always pre-prepared multiple propofol syringes; 5.0% diluted propofol and often/always pre-prepared syringes.
Conclusion: Penetration of the SASA Guidelines was low. Differences in unsafe practices among anaesthesiologists who had read 
the guidelines were statistically significant but clinically inconsequential. This highlights a need for greater publicity, emphasising 
their practical importance.
Keywords: drug compounding, Infection control, propofol, postoperative complications, practice guidelines as topic
Introduction
Anaesthetic workspaces in South Africa are prone to 
contamination, with subsequent risk of intraoperative 
transmission of pathogenic microorganisms.1,2 Propofol, being 
dissolved in a lipid emulsion of soya bean oil, glycerol and egg 
lecithin, is capable of supporting rapid bacterial and fungal 
growth3–12 as well as promoting endotoxin production.3 
Furthermore, stability of hepatitis C virus in propofol has been 
demonstrated.13 Reports of infections related to extrinsically 
contaminated propofol resulting from unsafe injection practices 
have appeared regularly since 1990.14–23 Centres for disease 
control and anaesthetic associations,24–29 including the South 
African (SA) Association of Anaesthesiologists (SASA)30 have 
published guidelines for prevention of anaesthetic-related 
infections. With regard to safe injection practices, all agree that 
syringes, needles, administration sets, ampoules and vials are for 
single use only and containers should be wiped with an alcohol 
swab before breaking the ampoule or penetrating the vial 
diaphragm. Furthermore, propofol should be discarded within 6 
h and in the intensive care unit (ICU) within 12 h. The United 
States of America’s Centers for Disease Control and Prevention 
(CDC) are conducting a ‘One and Only Campaign’ to raise 
awareness regarding safe injection practices amongst healthcare 
professionals and patients.31 Despite these efforts, it appears that 
in several countries unsafe injection practices persist among 
anaesthetists.32–35 The SA Medicines Control Council issued a 
warning during 2000 concerning outbreaks of postoperative 
infections, involving 10 patients (including one fatality) that 
resulted from unsafe injection practices involving propofol.36 
Recently a survey among 91 anaesthetists working in 15 hospitals 
in KwaZulu-Natal revealed that unsafe injection practices were 
common.37
The primary objectives of this study were: (1) To ascertain 
propofol injection practices among South African anaesthetists 
regarding the risk of infection transmission by means of a survey; 
(2) To determine the influence of the SASA Guidelines for 
Infection Control in Anaesthesia in South Africa 2014 (SASA 
Guidelines) on the propofol injection practices of SA 
anaesthetists. Secondary objectives were: (a) To determine 
whether propofol injection practices differed according to level 
of training (registered specialist vs. non-specialist), sector 
employed (private vs. public) and gender; (b) To estimate the 
prevalence of target-controlled infusions (TCI) among SA 
anaesthetists.
Methods
Approval for the study was obtained from the Health Research 
Ethics Committee (HREC) of the Faculty of Medicine & Health 
Sciences of Stellenbosch University, SA; (Institutional Review 
Board (IRB) Number: IRB0005239, Protocol Number S15/09/198). 
The survey was conducted in collaboration with the Anaesthesia 
Network for South Africa (ANSA), a SASA initiative that supports 
national collaborative research. Permission to conduct the 
survey amongst SASA members was obtained and ANSA was 
authorised by SASA to survey members on our behalf. SASA 
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Introduction
Anaesthetic workspaces in South Africa are prone to 
contamination, with subsequent risk of intraoperative 
transmission of pathogenic microorganisms.1,2 Propofol, being 
dissolved in a lipid emulsion of soya bean oil, glycerol and egg 
lecithin, is capable of supporting rapid bacterial and fungal 
growth3–12 as well as promoting endotoxin production.3 
Furthermore, stability of hepatitis C virus in propofol has been 
demonstrated.13 Reports of infections related to extrinsically 
contaminated propofol resulting from unsafe injection practices 
have appeared regularly since 1990.14–23 Centres for disease 
control and anaesthetic associations,24–29 including the South 
African (SA) Association of Anaesthesiologists (SASA)30 have 
published guidelines for prevention of anaesthetic-related 
infections. With regard to safe injection practices, all agree that 
syringes, needles, administration sets, ampoules and vials are for 
single use only and containers should be wiped with an alcohol 
swab before breaking the ampoule or penetrating the vial 
diaphragm. Furthermore, propofol should be discarded within 6 
h and in the intensive care unit (ICU) within 12 h. The United 
States of America’s Centers for Disease Control and Prevention 
(CDC) are conducting a ‘One and Only Campaign’ to raise 
awareness regarding safe injection practices amongst healthcare 
professionals and patients.31 Despite these efforts, it appears that 
in several countries unsafe injection practices persist among 
anaesthetists.32–35 The SA Medicines Control Council issued a 
warning during 2000 concerning outbreaks of postoperative 
infections, involving 10 patients (including one fatality) that 
resulted from unsafe injection practices involving propofol.36 
Recently a survey among 91 anaesthetists working in 15 hospitals 
in KwaZulu-Natal revealed that unsafe injection practices were 
common.37
The primary objectives of this study were: (1) To ascertain 
propofol injection practices among South African anaesthetists 
regarding the risk of infection transmission by means of a survey; 
(2) To determine the influence of the SASA Guidelines for 
Infection Control in Anaesthesia in South Africa 2014 (SASA 
Guidelines) on the propofol injection practices of SA 
anaesthetists. Secondary objectives were: (a) To determine 
whether propofol injection practices differed according to level 
of training (registered specialist vs. non-specialist), sector 
employed (private vs. public) and gender; (b) To estimate the 
prevalence of target-controlled infusions (TCI) among SA 
anaesthetists.
Methods
Approval for the study was obtained from the Health Research 
Ethics Committee (HREC) of the Faculty of Medicine & Health 
Sciences of Stellenbosch University, SA; (Institutional Review 
Board (IRB) Number: IRB0005239, Protocol Number S15/09/198). 
The survey was conducted in collaboration with the Anaesthesia 
Network for South Africa (ANSA), a SASA initiative that supports 
national collaborative research. Permission to conduct the 
survey amongst SASA members was obtained and ANSA was 
authorised by SASA to survey members on our behalf. SASA 
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membership is approximately 1 700. We included registrars, 
associate members (general practitioner anaesthetists) and 
specialist anaesthesiologists in public and private practice who 
were accessible by email. Nurse members and members residing 
in other countries were excluded. Retired members who did not 
respond to the survey invitation, and whose contact details had 
not been updated, were excluded. We developed the 
questionnaire and collected the data using the Research 
Electronic Data Capture Consortium (REDCap) system, a secure 
application developed at Vanderbilt University.38 The list of 
survey questions is presented in Appendix A.
An email invitation to participate in the survey was distributed to 
SASA members during November 2015. Potential participants 
were assured of anonymity, and informed about the purpose of 
the study and approval by SASA and HREC. By responding, the 
participant granted consent that his/her responses be used for 
the study. The invitation contained a link to the electronic 
questionnaire. Completed questionnaires were captured 
automatically and stored on a secure server. An incentive in the 
form of a prize could be won through a process of random 
selection. Non-responders received three reminders at 10-day 
intervals. Additional invitations to participate were distributed to 
non-responders during January 2016, followed by two reminders 
at 10-day intervals. We concluded the survey during February 
2016. The sponsor’s identity was revealed with the name of the 
prize-winner. Data were exported from the REDCap database to 
a comma-delimited file and imported to Microsoft Excel® 
(Microsoft Corp, Redmond, WA, USA).
Calculation of risk score
We constructed a risk-scoring system from the possible replies to 
13 questions regarding handling of propofol ampules and 
syringes that we regarded as constituting infection risks 
(Appendix B). For example, in reply to the question ‘Do you draw 
up leftover contents of a propofol glass ampule for the next 
patient?’, scores of 0, 1, 2 and 3 were allocated to the replies 
‘Never’, ‘Rarely’, ‘Often’ and ‘Always’ respectively. The maximum 
total was 39. Scores were grouped into Low-, Moderate-, High- 
and Very High-Risk categories (Appendix B, Table 2). Risk scores 
were applied to the replies by the respondents, who indicated 
that their practices included administration of propofol by 
infusion. Rubber-stoppered vial usage was not included in the 
risk-score calculations and was analysed separately because only 
a minority of respondents were propofol vial users.
Statistical analysis
Statistical analysis was performed using MedCalc software.39 
Non-parametric methods were employed, the data being 
ordered and categorical. Risk scores were compared using the 
Mann–Whitney test when comparing two groups and Kruskal–
Wallis one-way analysis of variance for more than two groups, 
followed by multiple comparisons. Proportional data were 
compared using the chi-square test. An alpha value < 0.05 was 
accepted as statistically significant. Confidence intervals for the 
differences between two median values were calculated using 
Confidence Interval Analysis (CIA) software.40 CIA employs the 
Hodges–Lehmann estimator for calculating a confidence interval 
between two population medians, described by Conover41 and 
outlined in the book Statistics with Confidence by Altman et al.42
Results
We issued 1 598 invitations and received 634 satisfactorily 
completed replies (39.7%). Participants’ mean age was 46.3 years 
(SD 11.6, range 26–78 years). Table 1 portrays their demographics 
as well as several key responses.
Risk-scores analysis
Risk scores were applied to the replies by the 542 respondents 
who indicated that they administered propofol by infusion. The 
median infection-risk score was 11 (Range 0–27; IQR 8–14; 95% 
confidence interval (95% CI) 10–11). One participant was 
classified as Very High risk. Participants’ scores and the frequency 
of scores in the various risk categories are portrayed in Figure 1 
and Table 2. The majority of the 542 participants (65%) were 
classified as Moderate- Risk. The next largest grouping was Low 
Risk (29%). High Risk and Very High Risk together comprised 6%.
Table 1: Demographics of and certain responses of interest by the 634 
respondents
Factor Proportion of total Number
Participants 100% 634
Females 36.3% 230
Private sector 66% 417
Registered specialists 77% 488
Trainees 13% 81
General practitioners 10% 65
Aware of SASA Guidelines 62% 393
Studied SASA Guidelines 29% 185
Read package insert 52% 332
Pre-prepares multiple syringes 45% 283
Pre-prepares often 21% 133
Pre-prepares always 3.6% 23
Sometimes dilutes propofol 18% 112
Often/always pre-prepares syringes 
and dilutes propofol
5.0% 32
Adds ketamine to propofol often/
always 
6.2% 39
Will draw up ketamine from previously 
used vial
16% 102
Adds remifentanil to propofol often/
always
14% 90
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Figure 1: Histogram illustrating the distribution of the risk scores of 
the 542 respondents who indicated that they administer propofol by 
infusion. Green = Low risk (0–8); Blue = Moderate risk (9–17); Red = High 
risk (18–26); Yellow = Very high risk (27–39).
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The extent to which the answers to each question contributed to 
the total of all the scores was obtained by calculating the total 
scores resulting from each of the 13 questions and expressing 
them as a percentage of the overall total (Table 3). The first five of 
the ranked responses contributed 75% to the total.
Impact of the SASA Guidelines on infection-risk scores
Of the 542 scored respondents, 332 (61.3%) were aware of the 
SASA Guidelines, of whom 157 (47.3%) had studied them (29% of 
the 542). The impact of the SASA Guidelines is presented in Table 
4 and Figure 2. The median risk score of those who had studied 
the SASA Guidelines was significantly lower than those who had 
not (p < 0.001); however, the difference was small (95% CI 1–2 
points). The studied-SASA-Guidelines group had a greater 
proportion of respondents who were categorised as Low Risk 
(58.4% vs. 45.2%, p = 0.0026) and a lower proportion who were 
categorised as Moderate Risk (38.4% vs. 50.8%, p = 0.0045). There 
was no difference between the proportions of High-Risk 
individuals (3.2% vs 4.0%, p = 0.646).
Of the 157 who had studied the guidelines, 56 (35.7%) stated 
that they had subsequently changed their practices: 55 stated 
how their practices had changed (Appendix C). There was no 
significant difference in median risk scores between those who 
stated that they had changed their practices vs. those who had 
not (9, IQR 7–12, vs. 10, IQR 7–13, p  =  0.12, Figure 3). None of 
those who stated that they had changed their practices achieved 
High-Risk scores, whereas eight of those who had not changed 
their practices did achieve High-Risk scores (median 18, range 
18–27, one-tailed probability for Fisher’s exact test p  =  0.026). 
There was no difference between the two groups with regard to 
the proportions who achieved Low-Risk scores (p = 1.0).
Influence of training level, employment sector, gender 
and age on infection-risk scores (Table 4)
The median score of non-specialists was statistically significantly 
smaller than that of the specialist group (p = 0.038); however, the 
difference was trivial (95% CI 0–2 points). There were no 
significant differences between the median scores of 
practitioners working in the private vs. the public sector or males 
vs. females. There was no association between age and risk score 
(Spearman’s rho = 0.003, p = 0.94).
Rubber-stoppered vial usage
Of the 634 respondents, 247 (40%) use rubber-stoppered vials. 
The majority (73.7%) worked in the private sector. Vial usage is 
depicted in Table 5. Notably with regard to low-risk behaviour, 
62.3% never share vial contents between patients; 21.1% stated 
that they always or often swabbed the diaphragm and never or 
seldom shared vial contents between patients. In terms of high-
risk behaviour, 57.9% never swab the diaphragm; 11.7% stated 
Table 2: Risk scores of the 542 participants who administer propofol by 
infusion, categorised from Low to Very High Risk
Notes: n = number of respondents (percentage of the 542 respondents).
IQR = interquartile range.
95% CI = 95% confidence interval of the median value.
Category n Median IQR Range 95% CI
Low (0–8) 156 (28.8%) 6 5–8 0–8 5.7–6.3
Moderate 
(9–17)
353 (65.1%) 12 10–14 9–14 10–12
High (18–26) 32 (5.9%) 19 18–20 18–26 18–19
Very High 
(27–39)
1 (0.2%) – – – –
Table 3: Contributions by the 542 ranked responses to the total number 
of infection-risk points. The first five ranked responses contributed 75% 
to the total score
Rank Participant response Points Proportion
1 Does not wipe neck of propofol am-
poule before breaking it
1532 25.6%
2 ICU propofol infusions: Change after 
> 12 h
900 15.1%
3 Propofol infusions: refills the 50 ml 
syringe
832 13.9%
4 More propofol for the same patient 
using a previously used syringe
667 11.2%
5 Uses a previously used needle to draw 
up more propofol
534 8.9%
6 Pre-prepares multiple propofol syringes 395 6.6%
7 Dilutes propofol 300 5.0%
8 Shares propofol ampoules between 
patients
297 5.0%
9 Infusions: Reuses 50 ml syringes be-
tween patients
179 3.0%
10 Bolus dosage: Reuses syringes between 
patients
135 2.3%
11 Carries over propofol from the a.m. to 
the p.m. list
102 1.7%
12 Uses the same extension tubing be-
tween patients
62 1.0%
13 In the OR: Time within which the 
propofol must be used after opening 
the ampoule
42 0.7%
  Total 5977 100%
Table 4: Risk scores according to various categories of respondents who 
administered propofol infusions (Total respondents 542)
Notes: n = number of respondents; IQR = interquartile range;.
95% CI Difference = 95% confidence interval of the difference between 
median scores.
Score categories: Low Risk 0–8; Moderate Risk 9–17; High Risk 18–26; 
Very High Risk 27–39.
Factor n Median 
(IQR)
Range p 95% CI 
Difference
Guide-
lines
Studied 157 10 2–27 0.001 1–2
(7–13)
Not 
studied
385 11 0–24
(9–14)
Sector Public 196 11 2–21 0.98 −1–1
(8–14)
Private 346 11 0–27
(8–14)
Training 
level
Specialist 414 11 0–27 0.038 0–2
(8–14)
Non-spe-
cialist
28 10 2–24
(8–12)
Gender Male 342 11 0–27 0.53 −1–1
(8–14)
Female 200 11 2–21
(8–14)
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points). The studied-SASA-Guidelines group had a greater 
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(58.4% vs. 45.2%, p = 0.0026) and a lower proportion who were 
categorised as Moderate Risk (38.4% vs. 50.8%, p = 0.0045). There 
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Table 4: Risk scores according to various categories of respondents who 
administered propofol infusions (Total respondents 542)
Notes: n = number of respondents; IQR = interquartile range;.
95% CI Difference = 95% confidence interval of the difference between 
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Private 346 11 0–27
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Training 
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that they never or seldom swabbed the diaphragm and always or 
often shared the vial contents.
Impact of the SASA Guidelines on rubber-stoppered 
vial usage
Seventy of the 247 respondents (28.3%) who use rubber-stoppered 
vials had studied the SASA Guidelines. The effect on those who 
had studied the SASA Guidelines is portrayed in Table 6.
Prevalence of target-controlled propofol infusions
Most (95.5%) respondents who administer propofol by infusion 
stated that they administered propofol by target-controlled 
infusion (TCI) (518/542). The median percentage of patients to 
whom these respondents administered TCI was 20% (IQR 10–
37%; 95% CI 17–21%; range 1–100%). Seventy-five respondents 
stated that they administered TCI for 75% or more of their cases. 
Figure 4 depicts a frequency histogram of the distribution of TCI 
infusions.
Discussion
Only 29% of participants who administer propofol infusions 
were classified as being of low risk, the majority (65%) scoring in 
the moderate-risk category. This is a disconcerting finding, as, in 
addition, a significant proportion (6%) scored as High Risk or 
Very High Risk. Prior to publication of the SASA Guidelines, a 
survey conducted among 91 anaesthetists in KwaZulu-Natal37 
found that 14% of the participants admitted to the reuse of 
syringes on different patients; 19% reused syringes on different 
patients after changing the needle or infusion set. Similar 
behaviour was demonstrated in our study, despite it being 
conducted after publication of the SASA Guidelines. In our study, 
16% admitted to using the same propofol syringe for different 
patients and 21% to reusing 50 ml syringes for propofol infusions. 
Of these, 30% reuse extension tubing between patients. Thus it 
appears that little change in clinical practice has occurred since 
publication of the SASA Guidelines. It is concerning that 44% of 
the total of 634 participants pre-prepared multiple syringes (21% 
often and 3.6% always). It is of particular concern that 8.8% of 
participants diluted the propofol and pre-prepared syringes. 
These actions are particularly prone to transmission of infection, 
considering the contaminated environment of many SA 
operating rooms and that pre-prepared syringes may end up 
being used some hours after preparation. Vial usage was also 
disconcerting as 57.9% indicated that they never swab the 
diaphragm with an alcohol swab. Only 21% always or often 
swabbed the diaphragm and never or seldom shared the 
contents between patients. Furthermore almost 12% never or 
seldom swabbed the diaphragm and always or often shared the 
vial contents. Studying the SASA Guidelines did influence vial 
handling significantly, as 40% often/always wiped the diaphragm 
and seldom/never shared vial contents between patients versus 
13.6% who had not studied the guidelines.
Failure to wipe the neck of the propofol ampoule made the 
greatest contribution to risk scores (Table 3). Zacher et al. 
demonstrated that wiping the ampoule neck with alcohol prior 
to opening significantly reduced bacterial contamination of 
propofol ampoules.43 This is of particular importance when 
preparing propofol infusions for TCI or total intravenous 
anaesthesia (TIVA), or for sedation during critical care, where the 
solution may be administered over several hours. The second 
major contributor related to the duration of propofol infusions in 
the intensive care unit (ICU) whereby participants were prepared 
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Figure 2: Box and whisker plots illustrating the influence of the South 
African Society Guidelines for Infection Control in Anaesthesia in South 
Africa 2014 on the infection risk scores of participants who had read 
them versus those who had not. Green = Low risk; Blue = Moderate 
risk; Red = High risk; Yellow = Very high risk. SASA Guidelines = South 
African Society Guidelines for Infection Control in Anaesthesia in South 
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Figure 3: Box and whisker plots illustrating infection risk scores of 
practitioners who, after having read the SASA guidelines, changed their 
practices vs. those who had not. Green = Low risk; Blue = Moderate risk; 
Red = High risk; Yellow = Very high risk.
Table 5: Rubber stoppered vial usage (247 respondents)
Note: Percentages are expressed as proportions of 247 respondents, 
unless stated otherwise.
Factor Total Always Often Rarely Never
Swab 
diaphragm 
with 
alcohol
104 34 25 45 143
(42.1%) (13.8%) (10.1%) (18.2%) (57.9%)
Allow 
diaphragm 
to dry (% 
of 104)
87 41 18 28 17
(83%) (39.4%) (17.3%) (26.9%) (16.3%)
Share 
contents
93 3 33 57 154
(37.7%) (1.2%) (13.4%) (23.1%) (62.3%)
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EDTA (ethylenediaminetetraacetic acid) can retard the 24-h 
growth of microorganisms 10-fold thereby reducing the 
microbial growth potential in propofol to that of a non-lipid 
medication.45,46 EDTA is an FDA-required antimicrobial propofol 
additive, which has reduced the incidence of propofol-related 
infections from an average of 39 to 9 infections per year.17 Three 
propofol formulations are in common use in SA, of which only 
one (Diprivan®, AstraZeneca) contains EDTA. The package insert 
stipulates that Diprivan is not an antimicrobially preserved agent; 
the EDTA retards bacterial growth, but does not prevent it, 
necessitating asepsis during propofol administration.
Some 62% of the total 634 respondents were aware of the SASA 
Guidelines but only 29% had studied them. Furthermore only 
52% had read a propofol package insert, in which manufacturers 
warn of the propensity of propofol emulsions to promote 
bacterial growth and the necessity for aseptic procedures. 
Studying the SASA Guidelines had a statistically significant 
impact on participants’ propofol handling practices. Besides 
achieving lower risk scores, those who had studied the guidelines 
had a greater proportion of low-risk scoring individuals and a 
smaller proportion with moderate-risk scores. However, both 
groups had similar proportions of high-risk scoring individuals. 
Results were analogous with regard to vial handling: Whereas 
those who had studied the SASA- Guidelines had a greater 
proportion of practitioners who demonstrated low-risk 
behaviour, both groups had similar proportions of individuals 
who admitted to high-risk habits. Thus moderate and high-risk 
behaviour persists despite studying the SASA Guidelines. We 
conclude that the influences exerted by the SASA Guidelines, 
although statistically significant, have been small and probably 
of no clinical importance.
This study’s disappointing result is not unique. A survey amongst 
493 American Society of Anesthesologists (ASA) members 
reported that 34.4% never or rarely swabbed rubber-stoppered 
vials and 20% often or always reused syringes.47 Those who had 
read the CDC guidelines for the prevention of occupational 
transmission of HIV/HBV were more likely to have good hygienic 
practices, but the association, although statistically significant, 
was weak (r2 = 0.036) and furthermore they were not more likely 
to swab vials than those who had not read the guidelines. A 
similar survey among 272 New Zealand anaesthetists34 reported 
that 32.4% had never read the national policy on infection 
control24; 86.3% reused ampules between patients, 41.3% reused 
vials and 2.2% reused syringes. A five-hospital audit in south-east 
England48 reported that only 49% of anaesthetists knew the 
Association of Anaesthetists guidelines. A survey among 1 015 
ASA members49 found that 58% reused syringes between 
patients and 66% reused needles to draw up drugs.
The large number of anaesthesiologists who practise TCI for a 
considerable number of cases indicates how readily the SA 
to allow more than 12 h to elapse before discarding propofol and 
giving sets. Of particular concern is that propofol intended for 
sedation is often diluted prior to administration, itself a risky 
action. Propofol package inserts clearly state that although 
propofol may be diluted with four parts of 5% glucose or 0.9% 
sodium chloride, it should be done aseptically. The United States 
Pharmacopeial Convention (USP) stipulates that compounding 
of medications should be conducted in an ISO-5 class 
environment (less than 3 520 particles of size 0.5 μm and larger 
per cubic metre) and that this is not achievable within the 
operating room environment.44
An appraisal of 58 studies regarding propofol-related infections, 
including 20 outbreaks involving 144 patients and 10 deaths,22 
identified syringes, micro-droppers, vials, and IV stopcock dead 
space as the most frequently encountered reservoirs of 
extrinsically contaminated propofol, with previously used vials 
being the most common culprits. Of the infection outbreaks, 
hepatitis C contributed 18.1%, hepatitis B 4.2%, Candida albicans 
21.5% and bacteria 47.2% (gram-positive 27.1%, gram-negative 
20.1%). The incidence of contaminated syringes was 
approximately 6% in ICUs and operating rooms. The authors 
point out that these reports were all from industrialised countries 
(USA, UK, Europe, Australia and Taiwan) and they were of the 
opinion that propofol-related infections are under-reported. No 
reports from developing or low-income countries have been 
forthcoming where the problem is likely to be much greater due 
to economic restraints and lack of awareness leading to reuse of 
syringes, ampoules and vials.
Table 6: Propofol vial usage: influence of the SASA Guidelines on high-risk and low-risk behaviour
Factor Studied SASA Guidelines (n = 70) Not-studied SASA Guidelines 
(n = 177)
p
High risk behaviour Share vial contents between patients 
often/always
14 (20%) 22 (12.4%) 0.13
Low risk behaviour Wipe diaphragm often/always AND share 
contents seldom/never
28 (40%) 24 (13.6%) < 0.0001
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Figure 4: Practitioners who administer propofol using target-controlled 
infusions (TCI): Histogram illustrating the percentages they administer 
by TCI. TCI proportion = the proportion that TCI comprises practitioners’ 
infusion administrations. N = number of practitioners; IQR = 
interquartile range.
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EDTA (ethylenediaminetetraacetic acid) can retard the 24-h 
growth of microorganisms 10-fold thereby reducing the 
microbial growth potential in propofol to that of a non-lipid 
medication.45,46 EDTA is an FDA-required antimicrobial propofol 
additive, which has reduced the incidence of propofol-related 
infections from an average of 39 to 9 infections per year.17 Three 
propofol formulations are in common use in SA, of which only 
one (Diprivan®, AstraZeneca) contains EDTA. The package insert 
stipulates that Diprivan is not an antimicrobially preserved agent; 
the EDTA retards bacterial growth, but does not prevent it, 
necessitating asepsis during propofol administration.
Some 62% of the total 634 respondents were aware of the SASA 
Guidelines but only 29% had studied them. Furthermore only 
52% had read a propofol package insert, in which manufacturers 
warn of the propensity of propofol emulsions to promote 
bacterial growth and the necessity for aseptic procedures. 
Studying the SASA Guidelines had a statistically significant 
impact on participants’ propofol handling practices. Besides 
achieving lower risk scores, those who had studied the guidelines 
had a greater proportion of low-risk scoring individuals and a 
smaller proportion with moderate-risk scores. However, both 
groups had similar proportions of high-risk scoring individuals. 
Results were analogous with regard to vial handling: Whereas 
those who had studied the SASA- Guidelines had a greater 
proportion of practitioners who demonstrated low-risk 
behaviour, both groups had similar proportions of individuals 
who admitted to high-risk habits. Thus moderate and high-risk 
behaviour persists despite studying the SASA Guidelines. We 
conclude that the influences exerted by the SASA Guidelines, 
although statistically significant, have been small and probably 
of no clinical importance.
This study’s disappointing result is not unique. A survey amongst 
493 American Society of Anesthesologists (ASA) members 
reported that 34.4% never or rarely swabbed rubber-stoppered 
vials and 20% often or always reused syringes.47 Those who had 
read the CDC guidelines for the prevention of occupational 
transmission of HIV/HBV were more likely to have good hygienic 
practices, but the association, although statistically significant, 
was weak (r2 = 0.036) and furthermore they were not more likely 
to swab vials than those who had not read the guidelines. A 
similar survey among 272 New Zealand anaesthetists34 reported 
that 32.4% had never read the national policy on infection 
control24; 86.3% reused ampules between patients, 41.3% reused 
vials and 2.2% reused syringes. A five-hospital audit in south-east 
England48 reported that only 49% of anaesthetists knew the 
Association of Anaesthetists guidelines. A survey among 1 015 
ASA members49 found that 58% reused syringes between 
patients and 66% reused needles to draw up drugs.
The large number of anaesthesiologists who practise TCI for a 
considerable number of cases indicates how readily the SA 
to allow more than 12 h to elapse before discarding propofol and 
giving sets. Of particular concern is that propofol intended for 
sedation is often diluted prior to administration, itself a risky 
action. Propofol package inserts clearly state that although 
propofol may be diluted with four parts of 5% glucose or 0.9% 
sodium chloride, it should be done aseptically. The United States 
Pharmacopeial Convention (USP) stipulates that compounding 
of medications should be conducted in an ISO-5 class 
environment (less than 3 520 particles of size 0.5 μm and larger 
per cubic metre) and that this is not achievable within the 
operating room environment.44
An appraisal of 58 studies regarding propofol-related infections, 
including 20 outbreaks involving 144 patients and 10 deaths,22 
identified syringes, micro-droppers, vials, and IV stopcock dead 
space as the most frequently encountered reservoirs of 
extrinsically contaminated propofol, with previously used vials 
being the most common culprits. Of the infection outbreaks, 
hepatitis C contributed 18.1%, hepatitis B 4.2%, Candida albicans 
21.5% and bacteria 47.2% (gram-positive 27.1%, gram-negative 
20.1%). The incidence of contaminated syringes was 
approximately 6% in ICUs and operating rooms. The authors 
point out that these reports were all from industrialised countries 
(USA, UK, Europe, Australia and Taiwan) and they were of the 
opinion that propofol-related infections are under-reported. No 
reports from developing or low-income countries have been 
forthcoming where the problem is likely to be much greater due 
to economic restraints and lack of awareness leading to reuse of 
syringes, ampoules and vials.
Table 6: Propofol vial usage: influence of the SASA Guidelines on high-risk and low-risk behaviour
Factor Studied SASA Guidelines (n = 70) Not-studied SASA Guidelines 
(n = 177)
p
High risk behaviour Share vial contents between patients 
often/always
14 (20%) 22 (12.4%) 0.13
Low risk behaviour Wipe diaphragm often/always AND share 
contents seldom/never
28 (40%) 24 (13.6%) < 0.0001
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Figure 4: Practitioners who administer propofol using target-controlled 
infusions (TCI): Histogram illustrating the percentages they administer 
by TCI. TCI proportion = the proportion that TCI comprises practitioners’ 
infusion administrations. N = number of practitioners; IQR = 
interquartile range.
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anaesthesiology profession has accepted the technology. 
However, because of the potential for long-duration infusions, 
our results emphasise the necessity for these practitioners to 
adopt safe injection practices.
Ketamine has been shown to exert antibacterial and antifungal 
activity50 and, considering that it is also pharmaceutically 
compatible with propofol,51 it may be argued that propofol–
ketamine mixtures may reduce the risk of infection due to 
extrinsic contamination. Begec et al.50 studied the growth rates 
of several micro-organisms and the minimal bactericidal 
concentrations of ketamine in mixtures with 1% propofol 
(without EDTA). Ketamine retained microbial activity for certain 
organisms, but at different concentrations. Growth of 
Staphylococcus aureus was not inhibited at the highest tested 
ketamine concentration. They warned that although propofol–
ketamine mixtures may reduce the risk of infection caused by 
accidental contamination, ketamine’s antibacterial activity 
varies and may be ineffective against certain pathogens. 
Furthermore we are not aware of studies documenting antiviral 
activity.
Apan et al. investigated the growth rates of several micro-
organisms in mixtures of remifentanil and 1% propofol.52 They 
demonstrated concentration-dependent growth retardation, 
which they attributed to the presence of glycine, a buffer in 
remifentanil ampoules. However, no bactericidal activity was 
demonstrated, necessitating aseptic precautions. It should be 
noted that mixing propofol with other drugs technically 
constitutes a ‘new drug’ not approved by the SA Medicines 
Control Council. This has medicolegal implications, as the 
anaesthesiologist assumes responsibility for any side-effects/
complications.
The response rate to our survey was 39.7%, similar to two 
previous surveys (41% and 44%),47,49 but lower than the Ryan 
study (61%).34 Contributing factors were technical problems 
experienced with the SASA website, necessitating repeated 
emails to ensure that all members received invitations. 
Furthermore invitations were sent under the auspices of ANSA, a 
newly established, little-known SASA entity, thus some members 
may have ignored the emails. Nevertheless we regard 634 
completed responses as a suitably representative sample of the 
SASA membership.
Weaknesses of this study include an unvalidated risk-scoring 
system, but it would be unethical to validate the system by 
means of a randomised controlled trial. Additionally we did not 
enquire into other important infection-control practices, 
specifically hand-washing and glove usage.
Conclusion
Persistent inadequacies regarding the safe administration of 
propofol reveal that the SASA Guidelines were of low impact. 
With regard to those who had studied the guidelines, statistically 
significant differences in injection practices were small and 
probably not clinically important. In addition, only 60% of 
respondents were aware of the SASA Guidelines, of whom less 
than half had read them. More effort is required to persuade SA 
anaesthetists to comply with the safe injection practices outlined 
by the SASA Guidelines as well as the package inserts of the 
propofol suppliers. It is noteworthy that no reports of infection 
associated with propofol usage have occurred where safe 
injection practices have been followed.53 Improved compliance 
is in the best interest of practitioners and patients alike.
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Appendix A: The questionnaire
Propofol usage survey
Invitation to take part in research about propofol usage
Dear anaesthetist
We, a combined study group from Stellenbosch University and the South African Society of Anaesthesiologists (SASA), invite you to 
take part in a survey concerning propofol injection practices by anaesthetists. It should not occupy more than five minutes of your time. 
The survey is completely anonymous and the data will be stored and encrypted in such a way that the identity of the participants 
cannot be retrieved. By participating you agree to your anonymous responses being used for research purposes. As participant, you will 
be eligible to win a sponsored prize (an iPad Mini). The Stellenbosch University Health Research Ethics Committee 1 has approved the 
study.
Please help us to gather as much accurate information as possible.
Sincerely
The propofol usage study group: JF Coetzee, H Kluyts, P Scheepers and A Breedt
What is your age?  
What is your gender? Male
Female
Are you A registered specialist in anaesthesiology?
A trainee/registrar?
A general practitioner?
Do you mainly work in Public sector?
Private sector?
Do you wipe the neck of a propofol glass ampoule* with an alcohol swab before breaking it? Never 
Rarely
Often
Always
(*Glass ampoule as opposed to a rubber-stop-
pered vial)
Do you allow the alcohol to dry before breaking open Never 
Rarely
Often
Always
Do you draw up leftover contents of a propofol glass ampoule* for the next patient? Never 
Rarely
Often
Always
(*Glass ampoule as opposed to rubber-stop-
pered vial)
Do you sometimes use propofol rubber-stoppered vials? Yes
No
Do you wipe the rubber diaphragm of a propofol vial with an alcohol swab before penetrating it with a needle? Never
Rarely
Often
Always
Do you allow the alcohol to dry before penetrating the diaphragm? Never
Rarely
Often
Always
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(Continued)
Do you use a rubber-stoppered propofol vial for more than one patient? Never
Rarely
Often
Always
Do you sometimes dilute propofol? Yes
No
Do you sometimes draw up more propofol for the same patient using the same previously used syringe? Never
Rarely
Often
Always
Do you use a new needle? Never
Rarely
Often
Always
Do you use the same propofol syringe for more than one patient? Never
Rarely
Often
Always
You are about to begin an operating list of short cases. Do you pre-prepare a number of propofol syringes before 
starting the first case?
Never
Rarely
Often
Always
Do you sometimes carry over propofol that has been drawn up into a syringe from your morning list to your after-
noon list?
Yes
No
Do you ever carry over any leftover propofol to the next day? Yes
No
Within what time frame should propofol be administered after drawing it up into a syringe? 6 hours
12 hours
24 hours
Do you administer propofol by infusion? Yes
No
For what proportion of cases do you administer propofol by target-controlled infusion (TCI)? 0
50%
100%
Do you refill the same 50 ml syringe for the same patient? Never
Rarely
Often
Always
Do you use the same 50 ml syringe for multiple patients? Never
Rarely
Often
Always
Do you use the same extension tubing between patients? Never
Rarely
Often
Always
Do you add remifentanil to the propofol syringe? Never
Rarely
Often
Always
Appendix A. (Continued)
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(Continued)
Do you use a rubber-stoppered propofol vial for more than one patient? Never
Rarely
Often
Always
Do you sometimes dilute propofol? Yes
No
Do you sometimes draw up more propofol for the same patient using the same previously used syringe? Never
Rarely
Often
Always
Do you use a new needle? Never
Rarely
Often
Always
Do you use the same propofol syringe for more than one patient? Never
Rarely
Often
Always
You are about to begin an operating list of short cases. Do you pre-prepare a number of propofol syringes before 
starting the first case?
Never
Rarely
Often
Always
Do you sometimes carry over propofol that has been drawn up into a syringe from your morning list to your after-
noon list?
Yes
No
Do you ever carry over any leftover propofol to the next day? Yes
No
Within what time frame should propofol be administered after drawing it up into a syringe? 6 hours
12 hours
24 hours
Do you administer propofol by infusion? Yes
No
For what proportion of cases do you administer propofol by target-controlled infusion (TCI)? 0
50%
100%
Do you refill the same 50 ml syringe for the same patient? Never
Rarely
Often
Always
Do you use the same 50 ml syringe for multiple patients? Never
Rarely
Often
Always
Do you use the same extension tubing between patients? Never
Rarely
Often
Always
Do you add remifentanil to the propofol syringe? Never
Rarely
Often
Always
Appendix A. (Continued)
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Do you add ketamine to the propofol syringe? Never
Rarely
Often
Always
Are you willing to use a previously used ketamine multidose vial? Yes
No
In the ICU, what is the maximum duration of a propofol infusion after which the giving set should be changed? 12 hours
24 hours 
36 hours 
48 hours 
Have you read the propofol package insert?  
Yes
No
Are you aware of the ‘SASA Guidelines for Infection Control in Anaesthesia in South Africa 2014’? Yes
No
Have you had an opportunity to read them? Yes
No
Having read the guidelines, have you changed your practice with regard to your handling of propofol? Yes
No
In what way have you changed your practice in the handling of propofol?  
Appendix B: Compilation of the infection-risk score
Q. 
No.
Question Possible answers and scores contributing to 
thresholds
Low risk Moderate 
risk
High risk Very high 
risk
1 Do you wipe the neck of a propofol glass ampoule with an alcohol swab before breaking it? Always (0) Often (1) Rarely (2) Never (3)
2 Do you draw up leftover contents of a propofol glass ampoule for the next patient? Never (0) Rarely (1) Often (2) Always (3)
3 Do you sometimes draw up more propofol for the same patient using the same previously used 
syringe?
Never (0) Rarely (1) Often (2) Always (3)
4 Do you use a new needle? Always (0) Often (1) Rarely (2) Never (3)
5 Do you use the same propofol syringe for more than one patient? Never (0) Rarely (1) Often (2) Always (3)
6 You are about to begin an operating list of short cases. Do you pre-prepare a number of propofol 
syringes before starting the first case?
Never (0) Rarely (1) Often (2) Always (3)
7 Do you refill the same 50 ml syringe for the same patient? Never (0) Rarely (1) Often (2) Always (3)
8 Do you use the same 50 ml syringe for multiple patients? Never (0) Rarely (1) Often (2) Always (3)
9 Do you use the same extension tubing between patients? Never (0) Rarely (1) Often (2) Always (3)
  Risk category thresholds   9 18 27
−23% −46% −69%
10 Do you sometimes dilute propofol? No (0) Yes (3)
11 Do you sometimes carry over propofol that has been drawn up into a syringe from your morning 
list to your afternoon list?
No (0)     Yes (3)
12 Within what time frame should propofol be administered after drawing it up into a syringe? 6 h (0)     12 h/24 h (3)
13 In the ICU, what is the maximum duration of a propofol infusion after which the giving set should 
be changed?
12 h (0)     24 h/36 h/ 
48 h (3)
Maximum possible score  = 39
Notes: Numbers in parentheses denote the number of points allotted to the corresponding answers.
ICU = intensive care unit.
Appendix A. (Continued)
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Appendix C:  Participant replies to ‘In what way have you changed your practice in the handling of propofol?’
Replies by the 62/185 participants who had studied the SASA Guidelines and stated that they had changed their practices to the 
question ‘In what way have you changed your practice in the handling of propofol?’
(1)  Use within 6 hours, no sharing.
(2)  1 patient 1 bottle/limit time propofol left standing discard if concerned.
(3)  Although this survey is testing an important aspect, as a consultant in a large state hospital I am privy to the practices of 
many anaesthetists. I believe the problem of contaminated drugs is much much bigger than merely drawing up the drug and 
capping the needle. The issue of actually administering the drug is much bigger. Who actually cleans the clave port before 
injecting. Often the syringes are just left uncapped. Also three-way taps are left uncapped etc. etc. … I keep reminding people 
to inject the drug in a manner that they would like for themselves.
(4)  Aware of infection control concerns specific to propofol ... wipe ampoule....
(5)  Changing syringes.
(6)  Discard left over propofol after 6 hours.
(7)  Discard leftover propofol.
(8)  Do not use single vial for more than one patient.
(9)  Do not use left over propofol for the next patient.
(10)  Duration after drawing up a syringe to discard it.
(11)  Far stricter in sterility and handling ampoules.
(12)  I am more conscious of the risk of infection, and I never use propofol after 6 hours of drawing it up.
(13)  I do not draw up propofol in advance.
(14)  I do not share multi-dose vials between patients.
(15)  I don’t reuse the same syringe for different patients with infusions.
(16)  I don’t use the same vial on multiple patients and I draw up the propofol as I am about to use it.
(17)  I now never use the same syringe for multiple patients and I no longer do amoule sharing.
(18)  I use a more sterile technique like wiping the ampoule with alcohol and letting it dry.
(19)  It must be used as soon as possible after opening.
(20)  Maintain proper sterility.
(21)  More care regarding septic risk.
(22)  More careful.
(23)  More conscious of contamination.
(24)  More stringent changing of needles and syringes for same patient, always changed between patients previously.
(25)  Never share.
(26)  Never share, use immediately following drawing into the syringe.
(27)  New needle and syringe.
(28)  New syringes. No multiple uses of 50 ml vial.
(29)  No more sharing of ampoules between patients, shorter time allowed before discarding leftovers, use new needles every 
time, only re-use the same 50 ml syringe for the same patient if nothing else available.
(30)  No sharing.
(31)  No Sharing; New syringes and needle; No carry-over.
(32)  No vial sharing.
(33)  Not drawing up early before case.
(34)  Not sharing ampoules any more.
(35)  Not sharing and not using syringes between pt. and not using left open ampoules.
(36)  Not to dilute propofol.
(37)  One patient only per vial/ampoule.
(38)  Opening practices.
(39)  Reduce time frame for administration.
(40)  Safer.
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(41)  Single use, aseptic technique.
(42)  Single patient per vial.
(43)  Single patient, single syringe.
(44)  Single use and draw up propofol just prior to administration.
(45)  Stopped using single vial for multiple patients.
(46)  Strict time limits to use propofol.
(47)  Stricter asepsis.
(48)  Swipe ampoules before use. Never put syringe in pocket any more.
(49)  Time to changing giving set.
(50)  To adhere to Infection Control Practices.
(51)  Use as soon as possible.
(52)  Use new propofol per patient.
(53)  Use within 6 hours.
(54)  Use within 4 hours after opening the ampoule. Use webcol to clean the neck of the ampoule.
(55)  Use within 6 hours of drawing up into syringe.
(56)  Using new syringes and not carrying propofol over to another patient or use after 6 hours.
(57)  Using new needles and syringes even when drawing propofol up for the same patient. Using one vial per patient i.e. not 
sharing. Not mixing drugs in the same syringe.
(58)  Vial opening and preparation.
(59)  Wipe.
(60)  Wiping the amp before breaking it.
(61)  Wiping with webcol.
(62)  Working more sterile.
